Karla Kerlikowske, MD; Shuai Chen, PhD; Michael C. S. Bissell, PhD; et al.
JAMA Oncol. 2024;10(2):167-175. doi:10.1001/jamaoncol.2023.5242
This cohort study evaluates the population attributable risk proportions for advanced-stage breast cancer associated with clinical risk factors among routinely screened women by race and ethnicity.
Naomi Takemura, PhD; Denise Shuk Ting Cheung, PhD; Daniel Yee Tak Fong, PhD; et al.
JAMA Oncol. 2024;10(2):176-184. doi:10.1001/jamaoncol.2023.5248
This randomized clinical trial compares the effectiveness of 2 physical activities of different modalities and intensities on subjective sleep quality, physical and psychological outcomes, and survival in patients with advanced lung cancer.
Krishnansu S. Tewari, MD; Nicoletta Colombo, MD, PhD; Bradley J. Monk, MD; et al.
JAMA Oncol. 2024;10(2):185-192. doi:10.1001/jamaoncol.2023.5410
This randomized clinical trial evaluates the efficacy and safety of adding pembrolizumab to platinum-based chemotherapy with or without bevacizumab in women with cervical carcinoma that was not amenable to curative treatment.
Brian D. Lehmann, PhD; Vandana G. Abramson, MD; E. Claire Dees, MD; et al.
open access
has audio
JAMA Oncol. 2024;10(2):193-201. doi:10.1001/jamaoncol.2023.5424
This randomized clinical trial examines the efficacy of adding atezolizumab to treatment with carboplatin in patients with metastatic triple-negative breast cancer (TNBC), and the clinical or molecular correlates associated with disease response.
-
Podcast:
Atezolizumab in Combination With Carboplatin in Metastatic TNBC
Sanne-Marije J. A. Hazen, MD; Tania C. Sluckin, MD; Martijn P. W. Intven, MD, PhD; et al.
JAMA Oncol. 2024;10(2):202-211. doi:10.1001/jamaoncol.2023.5444
This cross-sectional study examines the association of decreased use of neoadjuvant radiotherapy with cancer-related outcomes and overall survival.
Carolyn Horton, MS; Lily Hoang, BS; Heather Zimmermann, PhD; et al.
open access
JAMA Oncol. 2024;10(2):212-219. doi:10.1001/jamaoncol.2023.5586
This diagnostic study assesses the outcomes of paired DNA and RNA testing on detection of disease-causing germline genetic variants and resolution of variants of uncertain significance.
Ruihao Huang, MD; Ting Chen, MD; Sanbin Wang, MD; et al.
open access
JAMA Oncol. 2024;10(2):220-226. doi:10.1001/jamaoncol.2023.5757
This randomized clinical trial examines whether repeated infusions of mesenchymal stem cells during the early stage after haploidentical hematopoietic stem cell transplant decreases the incidence of severe chronic graft-vs-host disease.
Priyanka Sharma, MD; Shane R. Stecklein, MD, PhD; Rachel Yoder, MS; et al.
free access
JAMA Oncol. 2024;10(2):227-235. doi:10.1001/jamaoncol.2023.5033
This open-label phase 2 randomized clinical trial evaluates the clinical effects and biomarker findings of treatment with neoadjuvant pembrolizumab and carboplatin plus docetaxel in patients with triple-negative breast cancer.